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RESUMO
Introdução: A resistência à insulina é a chave fisiopatológica de explicação da Síndrome Metabólica. Apesar de claramente útil, o 
índice Homeostasis Model Assessment (uma medição da resistência à insulina) não tem sido aplicado sistematicamente na prática 
clínica. Uma das principais razões relaciona-se com a discrepância de valores limiares reportados em diferentes populações. Procurá-
mos avaliar uma população portuguesa o valor limiar ideal e avaliar a sua relação com a Síndrome Metabólica. 
Material e Métodos: Selecionámos uma coorte de indivíduos admitidos eletivamente numa enfermaria de cardiologia com um IMC 
< 25 Kg/m2 e sem anomalias do metabolismo da glicose (glicémia em jejum < 100 mg/dL e sem diabetes). Utilizámos o percentil 90 
da distribuição do índice Homeostasis Model Assessment para seleção do limiar adequado para resistência à insulina. Selecionou-
se também uma coorte de validação composta por 300 indivíduos, sem aplicação dos critérios de exclusão referidos anteriormente. 
Resultados: De uma população de 7 000 indivíduos e após aplicação dos critérios de exclusão, ficámos com 1 784 indivíduos para 
análise. O percentil 90 do índice foi 2,33. Na coorte de validação, aplicando esse limiar, 49,3% dos indivíduos apresentam resistência 
à insulina. Contudo, apenas 69,9% dos doentes com síndrome metabólica apresentam resistência à insulina com esse limiar. Por 
análise das curvas ROC, o limiar ideal para síndrome metabólica é 2,41. O índice Homeostasis Model Assessment correlacionou-se 
com o IMC (r = 0,371, p < 0,001) e é um preditor independente de presença de síndrome metabólica (OR 19,4, IC 95% 6,6 – 57,2, 
p < 0,001).
Discussão: O nosso estudo mostrou que numa população portuguesa de doentes admitidos eletivamente numa enfermaria de car-
diologia, o limiar pelo índice Homeostasis Model Assessment para resistência à insulina é 2,33 e para síndrome metabólica é 2,41. 
Conclusão: O índice Homeostasis Model Assessment correlacionou-se com o IMC e é um preditor independente de síndrome 
metabólica.
Palavras-chave: Teste de Tolerância a Glicose; Homeostase; Resistência à Insulina; Síndrome Metabólica; Doenças Cardiovasculares.
ABSTRACT
Introduction: Insulin resistance is the pathophysiological key to explain metabolic syndrome. Although clearly useful, the Homeostasis 
Model Assessment index (an insulin resistance measurement) hasn’t been systematically applied in clinical practice. One of the main 
reasons is the discrepancy in cut-off values reported in different populations. We sought to evaluate in a Portuguese population the 
ideal cut-off for Homeostasis Model Assessment index and assess its relationship with metabolic syndrome.
Material and Methods: We selected a cohort of individuals admitted electively in a Cardiology ward with a BMI < 25 Kg/m2 and no 
abnormalities in glucose metabolism (fasting plasma glucose < 100 mg/dL and no diabetes). The 90th percentile of the Homeostasis 
Model Assessment index distribution was used to obtain the ideal cut-off for insulin resistance. We also selected a validation cohort of 
300 individuals (no exclusion criteria applied).
Results: From 7 000 individuals, and after the exclusion criteria, there were left 1 784 individuals. The 90th percentile for Homeostasis 
Model Assessment index was 2.33. In the validation cohort, applying that cut-off, we have 49.3% of individuals with insulin resistance. 
However, only 69.9% of the metabolic syndrome patients had insulin resistance according to that cut-off. By ROC curve analysis, the 
ideal cut-off for metabolic syndrome is 2.41. Homeostasis Model Assessment index correlated with BMI (r = 0.371, p < 0.001) and is an 
independent predictor of the presence of metabolic syndrome (OR 19.4, 95% CI 6.6 – 57.2, p < 0.001).
Discussion: Our study showed that in a Portuguese population of patients admitted electively in a Cardiology ward, 2.33 is the 
Homeostasis Model Assessment index cut-off for insulin resistance and 2.41 for metabolic syndrome. 
Conclusion: Homeostasis Model Assessment index is directly correlated with BMI and is an independent predictor of metabolic 
syndrome.
Keywords: Glucose Tolerance Test; Homeostasis; Insulin Resistance Metabolic Syndrome.
.
INTRODUCTION
 Cardiovascular diseases are the leading cause of death 
in developed countries, including Portugal, not only as far 
as ischemic heart disease is concerned, but particularly in 
terms of stroke, the incidence of which is among the high-
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est in the world.1 In fact, in developed countries, the most 
common cardiovascular disease is ischemic heart disease, 
which is also the leading cause of death in all European 
Union with the exception of Greece, the former Yugoslavia 
Republic of Macedonia and Portugal, where it is stroke.2 
Clinically it is of great significance the identification of pa-
tients at risk of developing cardiovascular events to enable 
preventive interventions and to promote life style changes. 
 Overweight and obesity have risen dramatically in 
developed countries, resulting in a marked increase 
in metabolic syndrome, a clustering of cardiovascular 
risk factors including central adiposity, hypertension, 
dyslipidemia, and a proinflammatory state, conferring risk 
of atherosclerotic cardiovascular disease. Traditional risk 
prediction scores have proven very useful in identifying 
persons at risk for coronary heart disease, but such tools 
have limitations. Metabolic syndrome is one of such risk 
factors, but not included in the most common risk scores. 
Insulin resistance is the cornerstone of metabolic syndrome 
and a simple measurement can be used to detect it.3 The 
standard technique for assessment of insulin sensitivity is 
the hyperinsulinemic euglycemic clamp.4 However, although 
clamp technology has been applied to the study of insulin 
sensitivity and insulin secretion, it is time consuming and 
difficult to apply in clinical practice. Several non-invasive 
measurement techniques have been proposed, such as 
the fasting glucose / insulin ratio (FGIR), quantitative insulin 
sensitivity check index (QUICKI) and the Homeostasis 
Model Assessment (HOMA) index and each correlated 
reasonably well with clamp techniques.5-9 The HOMA 
approach, introduced by Matthews et al has been widely 
used in clinical research to assess insulin sensitivity.7,10-13 
However in clinical practice it is underused and the best 
cut-off is debated. Previous studies showed significant 
differences in insulin levels in different countries including 
European countries.14 This might have some impact in 
HOMA index reference levels and it calls for regional studies. 
In a literature review, no study was found in Portugal, where 
lower levels of insulin were previously reported.
 In the present study, we aimed to determine insulin and 
HOMA index levels in a population of patients admitted 
electively in a Cardiology ward. We also sought to determine 
the ideal cut-off for insulin resistance and metabolic 
syndrome.
MATERIAL AND METHODS
 The present study is an observational and cross- 
-sectional study, with prospective inclusion of patients 
admitted for an elective cardiac procedure (coronary 
angiography / angioplasty, electrophysiological study 
/ ablation, atrial septal defect / patent foramen ovale 
percutaneous closure, pacemaker / cardiac defibrillator / 
cardiac resynchronization therapy device implantation, or 
other procedure) between 2005 and 2011. All patients had 
an age ≥ 18 years. The local institutional ethics committee 
approved the study and all patients gave their written 
informed consent. 
 Anthropometrical data were obtained after a 12-hour 
fast, with the subject in light clothing and barefoot. Body 
weight was measured to the nearest kilogram using a digital 
scale, and height to the nearest centimetre in the standing 
position. Body Mass Index (BMI) was calculated as weight 
in kilograms divided by the height in meters, squared. 
Waist circumference (WC) was measured to the nearest 
centimetre, with the subject standing, using a flexible and 
non-distensible tape, midway between the lower limit of the 
rib cage and the iliac crest. 
 Blood pressure was measured on several occasions 
during hospital stay and hypertension was defined by 
a previous diagnosis of hypertension, use of specific 
medication or the presence of systolic blood pressure ≥ 
140 mmHg or diastolic blood pressure ≥ 90 mmHg (mean 
of three consecutive measurements). Patients that smoked 
during the previous six months were classified as smokers 
and were self-reported. 
 A venous blood sample was drawn after a 12-hour 
overnight fast. All the samples were analysed at the central 
laboratory of the hospital. Total cholesterol and triglycerides 
were determined using automatic standard routine enzymatic 
methods. HDL-cholesterol was determined after specific 
precipitation. LDL-cholesterol was determined by Friedwald 
formula. Blood glucose was analysed with the glucose-
oxidase method (intra-assay coefficient of variation: 2.0%). 
Blood insulin was analysed by electrochemilumenescence 
– ECLIA (intra-assay coefficient of variation: 3.5%). The 
assays used were the same throughout the study. The 
Homeostasis Model Assessment (HOMA) index was 
calculated by the following equation: fasting blood glucose 
(mg/dL) x fasting blood insulin (mcU/mL) / 405.7
 Metabolic syndrome was defined by the most recent 
definition from the American Heart Association / National 
Heart, Lung and Blood Institute (AHA/NHLBI) in which 
patients had to fulfil ≥ 3 of the following criteria: fasting 
glucose ≥ 100 mg/dL or specific medication; blood pressure 
≥ 130/85 mmHg or specific medication; triglycerides ≥ 150 
mg/dL or specific treatment for this lipid abnormality; HDL-
cholesterol < 50 mg/dL in women and < 40 mg/dL in men or 
specific treatment for this lipid abnormality; WC ≥ 88 cm in 
women and ≥ 102 cm in men.15 Diabetes was recorded by 
the investigator based in patient history, increased glucose 
(fasting level ≥ 126 mg/dL), or concomitant use of specific 
therapies. Patients did not stop their usual medication, 
except for the specific medication for diabetes which was 
suspended 24-48 hours before admission.
 From a sample of 7 000 consecutive patients, we 
excluded patients with a BMI ≥ 25 Kg/m2 (overweight or 
obese) or with abnormal glucose regulation (AGR): diabetics 
or with an impaired fasting glucose (blood glucose ≥ 100 
mg/dL). The cut-off for insulin resistance was obtained from 
this selected cohort. 
 We used another cohort of 300 patients (included in a 
specific doctoral research conducted between 2008 and 
2011) and not included in the previous group of patients, 
as a validation cohort of the obtained cut-off. This validation 
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cohort included individuals similar to the previous 7 000 
patients sample, but the exclusion criteria were not applied.
Informed consent has been obtained from each patient 
included in the study after explanation of the purpose and 
nature of all procedures used. Investigation was approved 
by the local ethical committee.
 
Statistical analysis
 Statistical analysis was conducted using the PASW 18.0 
statistical package (SPSS Inc, IL, Chicago, USA). A p-value 
< 0.05 was considered statistically significant. 
 Quantitative variables were described as mean and 
standard deviation, or as median values and corresponding 
25th and 75th percentiles for non-normally distributed variables 
and qualitative variables as percentages. Mann-Whitney’s 
U-test or Kruskal-Wallis test were used, as appropriate, for 
between-.groups comparisons of continuous variables while 
chi-square test was used for between-group comparisons 
of categorical variables. Pearson’s correlation was done 
between continuous variables. Simple and multiple logistic 
regression analysis were performed to determine if HOMA 
index is an independent predictor of metabolic syndrome. 
 The cut-off value for insulin resistance was based on 
the 90th percentile in the selected study cohort (non-obese 
and without abnormal glucose regulation). For metabolic 
syndrome, a receiver-operating characteristic (ROC) curve 
was generated from the validation cohort. The area under 
the ROC curve (AUC) was calculated to evaluate the 
predictive value of HOMA index for metabolic syndrome 
and to determine its best cut-off. The optimal cut-off value 
was denoted by the value that had the largest sum of 
sensitivity and specificity, and, at the same time, sensitivity 
and specificity ≥ 60%. 
RESULTS
 From the initial 7 000 patients analysed, 5 110 (73%) 
were initially excluded due to overweight or obesity and 
another 206 patients were excluded due to diabetes or 
impaired fasting glucose. The final study cohort included 
1784 individuals. The validation cohort included 300 
patients (55.3% with metabolic syndrome). Characteristics 
of both cohorts are described in Table 1. Patients in the 
selected study cohort were younger, less frequently males, 
with fewer risk factors for coronary disease and with a better 
metabolic profile (except for total and LDL-cholesterol). This 
was expected since this group has non-obese and without 
AGR patients. Both fasting plasma insulin (FPI) and HOMA 
index (Fig. 1) have a skewed distribution. FPI ranged from 
0.2 to 68.7 and HOMA index ranged from 0.03 to 16.62.
 Plasma blood glucose increased significantly with age 
until the age of 60 years, after which it remains stable. 
The same was observed for FPI and HOMA index, with a 
slight decrease in the very aged group (Table 2). According 
to gender, females had lower blood glucose and high FPI. 
However, HOMA index was not significantly different (Table 
2). There is a very significant and progressive increase of 
both FPI and HOMA according to BMI increase (p < 0.001) 
(Table 3). We also found a significant correlation between 
BMI and FPI (r = 0.389, p < 0.001) as well as with HOMA 
index (r = 0.371, p < 0.001). HOMA index is significantly 
higher in patients with metabolic syndrome [3.14 (2.01 
– 5.05) vs. 1.67 (1.05 – 2.28), p < 0.001], confirming the 
close association between insulin resistance and metabolic 
syndrome. Even in the non-diabetic group, this difference 
was significant [2.97 (1.80 – 6.46) vs. 1.49 (0.89 – 2.06), 
p < 0.001]
 The ideal HOMA index cut-off for insulin resistance 
obtained from the selected study cohort is 2.33. In the 
Table 1 – Characteristics of the study population and by gender
Characteristics
Validation cohort
n = 300
Study cohort
n = 1 784 p-value
Age (years) 64.4 ± 9.2 58.1 ± 18.2 0.020
Male gender (%) 59 51 0.012
Risk factors (%)
     Hypertension 79 62 < 0.001
     Hyperlipidemia 70 52 < 0.001
     Smoking   9 14    0.023
     Diabetes mellitus 23   0 < 0.001
Laboratorial data
     Glucose (mg/dL) 100 (92 –115) 86 (79 - 92) < 0.001
     Total cholesterol (mg/dL) 181 (155 – 213) 184 (156 - 212)    0.989
     HDL-cholesterol (mg/dL) 43 (36 – 54) 51 (42 - 61)    0.002
     LDL-cholesterol (mg/dL) 114 (93 – 136) 117 (96 - 141)    0.565
     Triglycerides (mg/dL) 97 (68 – 134) 81 (60 - 115)    0.006
     Insulin (mcU/mL) 8.6 (5.7 – 13.6) 5.0 (3.3 – 7.4) < 0.001
     HOMA index 2.3 (1.4 – 3.8) 1.1 (0.6 – 1.6) < 0.001
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validation cohort, using that cut-off, we have 49.3% of 
individuals with insulin resistance. However, only 69.9% 
of the patients with metabolic syndrome have insulin 
resistance and 23.9% of the patients without metabolic 
syndrome have insulin resistance (p < 0.001). Also, only 
78.4% of the individuals with insulin resistance have 
metabolic syndrome.
 By ROC curve analysis in the validation cohort, the 
HOMA index cut-off for metabolic syndrome is 2.41, with 
good discriminative performance (AUC 0.78, 95% CI 0.73 
– 0.83, p < 0,001, sensitivity 68.7%, specificity 79.5%). In 
a multivariate regression analysis, HOMA index (adjusted 
for age, gender and BMI) is an independent predictor of the 
presence of metabolic syndrome (OR 19.4, 95% CI 6.6 – 
57.2, p < 0.001).
DISCUSSION
 Previous studies showed some discrepancies in insulin 
levels amongst different countries worldwide and even in 
European countries. In fact, the European Fat Distribution 
Study (EFDS), conducted in European countries, in 
individuals with similar age and gender, showed significant 
 
Figure 1 – Distribution of HOMA index values in the study cohort
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Table 2 – Blood glucose, insulin and HOMA index according to age group and gender in the entire baseline study cohort (before exclusion 
criteria were applied; n = 7 000)
Glucose
(mg/dL)
Insulin
(mcU/mL)
HOMA index
< 40 years (n = 845) 82 (76 – 89) 6.0 (3,7 – 9.3) 1.2 (0.7 – 2.0)
40 – 49 years (n = 709) 86 (79 – 92) 6.0 (3.9 – 9.6) 1.2 (0.7 – 2.0)
50 – 59 years (n = 1 260) 89 (83 – 94) 6.7 (4.2 – 10.0) 1.4 (0.8 – 2.2)
60 – 69 years (n = 1 725) 89 (83 – 94) 6.4 (4.0 – 9.8) 1.4 (0.8 – 2.2)
≥ 70 years (n = 2 461) 89 (83 – 94) 6.1 (4.1 – 9.1) 1.3 (0.9 – 2.0)
     p-value < 0.001 0.043 0.001
Males (n = 3 892) 89 (82 – 94) 6.1 (3.9 – 9.5) 1.3 (0.8 – 2.1)
Females (n = 3 108) 87 (80 – 93) 6.4 (4.2 – 9.5) 1.4 (0.8 – 2.1)
     p-value < 0.001 0.047 0.265
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differences in FPI concentrations among different European 
countries: the lowest value was found in Italy and Portugal 
and the highest in Sweden and The Netherlands.14 This 
difference was explained by diet and genetic factors. These 
results support the need for regional studies, since results 
cannot be generalized for all countries. For that reason, we 
decided to conduct a study on that subject in a Portuguese 
population. 
 HOMA index is a surrogate index widely used to study 
the role of insulin sensitivity / resistance in association with 
disease states. However, reported values for the definition 
of insulin resistance vary widely. Also the cut-off points to 
diagnose insulin resistance cannot be readily applied to 
all populations and may vary from race to race.16 In the 
literature, several cut-off values of HOMA index for insulin 
resistance obtained from population studies in non-obese 
subjects with no metabolic disorders have been suggested 
based on different measures of dispersion. The better 
method is still in debate.
 Several methods have been used: 75th percentile, 90th 
percentile, lower boundary of the top quintile or tertile and 
others. Some authors also used ROC curves for cut-off 
estimation. Using the 75th percentile, it was reported a cut-
off of 1.81 in Japanese middle-aged man, 1.8 in individuals 
from Iran, and higher values in Spain (2.51) and China (2.67 
in females and 2.48 in males).16-19 Most authors use the 90th 
percentile. With that methodology, our cut-off is 2.33. This 
is slightly lower that the values described in Argentineans 
(2.64), Brazilians (2.7), Italians (2.77), and North Americans 
(2.7), and higher than Japanese (1.8).20-24 In a Spanish 
population the cut-off obtained was significantly higher 
(3.8).10 Inclusion and exclusion criteria were somewhat 
different between studies. In our study cohort, we only 
excluded patients with overweight / obesity and AGR. Other 
studies were more restrictive and also excluded patients 
with hypertension and lipid changes. Since our population 
of patients were admitted in a cardiology ward due to heart 
disease, these risk factors are extremely common. If these 
patients were excluded, our sample would be much smaller 
and less reliable. However, we do not think that hypertension 
or lipid abnormalities would have a major impact in glucose 
and insulin metabolism. Genetic background might be an 
important explanation for the different cut-points obtained. 
The cut-off for metabolic syndrome is similar (2.41) and the 
predictiveness of HOMA index for metabolic syndrome was 
similar to other authors.21
 We confirmed an increase in HOMA index up to 60 
years with subsequent stabilization. There was however 
a strong relationship with BMI. Other authors showed 
a significant age trend for HOMA index.25,26 A particular 
study in a Spanish population showed an increase in blood 
glucose, FPI and HOMA with increasing age, as in our 
study.18 However, this increase was explained by a higher 
prevalence of obesity and AGR that are known to increase 
with age. In fact, body composition changes, particularly in 
body fat distribution, which may contribute to the impairment 
in glucose metabolism occurring with aging. In the Spanish 
study, in non-obese subjects without AGR, HOMA index 
levels were not modified with age.18 In our study, BMI was 
highly correlated with HOMA index, with similar results as 
those obtained in the European Fat Distribution study.14 
There was also no gender difference in HOMA index, as 
previously described by other authors. 
 Pathophysiologicaly, insulin resistance is the key 
to metabolic syndrome.3 In fact, it is described a close 
relationship of HOMA index and all the components of 
metabolic syndrome.3,27-30 This is an established index and 
used in most epidemiological studies. However in clinical 
practice it is rarely used. As in other studies, patients with 
metabolic syndrome have a HOMA index significantly higher, 
even after the exclusion of diabetic patients.12 However 
only 69.9% of the patients with metabolic syndrome have 
insulin resistance. This result is similar to other authors 
and challenges once again insulin resistance as the sole 
pathophysiological mechanism for metabolic syndrome as 
some authors claim.
 Patients with cardiovascular disease are usually 
heavily medicated with some drugs that might have 
some implications in glucose regulation. The proportion 
of individuals on statin therapy was 38% in the selected 
study cohort and 59% in the validation cohort.  Although 
statin therapy is widely used and safe, conflicting data 
exist regarding the effects of some statins on the risk 
of incident type 2 diabetes. A meta-analysis of 13 statin 
trials showed an increase in the risk for diabetes over 
four years that might be dose related.31,32 However, none 
of the trials were designed to look for incident diabetes. 
Further studies are therefore required to fully understand 
this effect. Mechanisms explaining the potential higher 
incidence of diabetes with statin therapy have not yet been 
identified. The effect on glycaemic control were deemed to 
be unrelated to lipid profile.33 In our selected study cohort, 
we found an association between statin therapy and HOMA 
index (linear regression, β = 0.076, p < 0.001), even after 
adjustment for BMI (β = 0.054, p = 0.024). This has some 
implications in our results, because they can only be applied 
in similar populations. But in general practice, the proportion 
of patients on statin therapy is close to the one found in our 
study group.
 Our study has other limitations that should be 
mentioned. This is a single centre study and the results 
might not be translated to the general population. However, 
patients’ characteristics are similar to the patients followed 
by general practitioners.
Table 3 – Insulin and HOMA index according to BMI group in the 
baseline study cohort
Insulin
(mcU/mL)
HOMA index
Normal (n = 1 890) 6.4 (4.2 – 9.7) 1.6 (0.9 – 2.6)
Overweight (n = 3 300) 8.1 (5.5 – 11.5) 2.3 (1.2 – 3.4)
Obese (n = 1 810) 13.4 (7.7 – 21.8) 3.6 (2.3 – 5.9)
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 The absolute values of both the FPI and the HOMA index 
depend on the test characteristics of the insulin assay, and 
so the absolute values of FPI and HOMA measurements in 
the present study may differ from values obtained with other 
insulin assays.
 There are two computational methods for HOMA 
assessment. One uses the original HOMA model formula 
and the other is an online calculator computer model. A study 
showed that the two methods have different cut-offs for the 
definition of insulin resistance (2.5 and 1.4, respectively) and 
the first has higher association with metabolic syndrome.34 
Our study used the manual calculation, so it does not apply 
to online calculator computed values.
 Stress might influence blood glucose and FPI. All 
patients were admitted for a cardiac procedure, with some 
stress associated. However, since HOMA index is a ratio 
that includes both insulin and glucose, this effect might 
be minimized. Also, simple procedures such as blood 
drawing, as in the case for the euglycemic clamp technique 
(a standard technique to evaluate insulin resistance) can 
cause some stress for patients and this is considered 
acceptable for the measurement of insulin resistance.
CONCLUSION
 Our study showed that in a Portuguese population of 
patients admitted electively in a Cardiology ward, 2.33 is 
the HOMA index cut-off for insulin resistance and 2.41 for 
metabolic syndrome. HOMA index is directly correlated with 
BMI and is an independent predictor of metabolic syndrome.
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